stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
120.49
1.36
+1.14%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Shares outstanding
GRAIL, Inc.'s shares outstanding at the end of fiscal 2025 was $36.8M, up 15.2% from $31.9M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $46.8M. GRAIL, Inc. ranks 29th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $36.8M | 15.21% |
| FY2024 | $31.9M | 2.74% |
| FY2023 | $31.0M | 0.00% |
| FY2022 | $31.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $46.8M | 8.50% |
| Jun 2026 | $43.1M | 6.08% |
| Mar 2026 | $40.6M | 10.58% |
| Dec 2025 | $36.8M | 1.74% |
| 9 more quarters | Free account |
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company compare | $289.2M |
| QGEN QIAGEN N.V. compare | $207.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| VCYT Veracyte, Inc. compare | $82.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| ICLR ICON PLC compare | $77.4M |
| CDNA CareDx, Inc. compare | $55.0M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| GRAL GRAIL, Inc. | $46.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- Revenue growth
- The full statement